WillItSurvive
Financial data and information services · India

CARE Ratings (CareEdge)

careratings.com ↗

India's second-largest credit rating agency, rating bonds and issuers under SEBI rules.

Hard to displace
Assessed 21 July 2026 · Evidence as of 21 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 21 July 2026 · Checkable from 6 August 2026 · Every call on the record Checkpoint: Q1 FY27 results announcement
The call

CARE Ratings sits inside a regulated oligopoly where SEBI licensing and decades of default data keep both AI tools and bigger rivals like CRISIL from displacing it, even as CRISIL stays far larger.

CARE Ratings tells investors and banks whether Indian companies can repay their debts. It's hard to replace because Indian regulators require new raters to register with SEBI, and CARE has 33 years of historical data on which companies actually defaulted, a record competitors cannot quickly build. CRISIL (the #1 player, owned by S&P Global) dominates with about 65 percent market share but hasn't attacked CARE's turf, suggesting both companies are comfortable splitting the market. The real threat isn't a new competitor or artificial intelligence, since AI cannot legally issue ratings in India without liability, but if CARE loses the government's trust due to a credibility scandal, its entire protection collapses. CARE has faced fines and enforcement actions before (2020 to 2023), so any fresh regulatory embarrassment could hurt the company's standing.

Why
01
AI pressure: In-house and third-party AI analytics tools for credit research. AI speeds up data-crunching and drafting inside CARE's own process, boosting margins rather than replacing the regulated rating opinion. Could AI do the core job? Unlikely.
02
Bigger players: CRISIL (S&P Global subsidiary). CRISIL already holds roughly 65% of the domestic ratings market and keeps operating at multiples of CARE's size, though it is not visibly pulling business away. Could a giant copy it? No, they are blocked.
03
What protects it. SEBI registration is required to issue ratings with legal weight, and that license, plus 33 years of default data, blocks both new entrants and AI models.
What would change this call
SEBI issues any fresh enforcement action or fine against CARE Ratings itself. Would directly damage the regulatory-trust moat protecting CARE's business.
CARE Ratings' Q1 FY27 results (due around 6 August 2026) show revenue or profit growth slowing sharply. Would signal bond-market cyclicality is compressing the core ratings revenue.
SEBI proposes or ships a licensing framework allowing algorithmic or AI-based raters outside the full CRA regime. Would weaken the regulatory barrier currently blocking AI-driven competition.
Key numbers
  • FY26 consolidated revenue: ₹473.07 crore, up 18% YoY (2026-03-31)
  • FY26 consolidated profit: ₹173.69 crore, up 24% YoY (2026-03-31)
  • CareEdge Global now rates issuers in 45 countries (2026-05-29)
Named risks
  • Regulatory history of SEBI fines (2020) and a 2023 MD ban over DHFL rating interference could recur and damage core regulatory-trust moat. Severity: high
  • Revenue tied to corporate bond and commercial paper issuance volumes, which fell 11.3% YoY in Q4 FY26, exposing cyclicality. Severity: medium
  • Potential SEBI move to license AI/algorithmic raters outside the full CRA framework could weaken the regulatory seal. Severity: medium
  • Headcount and hiring growth (1.67% to 2.4% YoY) trail revenue growth, signalling reliance on productivity/AI gains that could mask analyst-quality strain. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
CRISIL Ratingslosing toCRISIL holds ~65% Indian CRA market share and 5-6x CARE's market cap as of mid-2026
ICRA LimitedcontestingICRA market cap ~₹5,000-5,100 crore, comparable to CARE's, as of July 2026
India Ratings (Fitch)contestingOne of three-plus Indian domestic CRAs competing for issuer mandates, 2026
Acuite Ratings and Brickwork Ratingsgaining onCARE's FY26 revenue grew 18% even as sector bond issuance fell 11.3% YoY in Q4 FY26
Questions people ask
Is CARE Ratings profitable in 2026?
Yes. CARE Ratings Limited (CareEdge) reported FY26 consolidated revenue of ₹473.07 crore, up 18% year on year, and consolidated net profit of ₹173.69 crore, up 24% YoY, its highest-ever profit, for the year ended 31 March 2026.
Could AI replace CARE Ratings' analysts?
Unlikely soon. CARE Ratings is a SEBI-registered credit rating agency; only licensed CRAs can issue legally-liable ratings mandated by Indian regulation. Management stated in its FY26 press release that new AI tools 'complement rather than replace expert judgement' in rating decisions.
Who is CARE Ratings' biggest competitor?
CRISIL Ratings, majority owned by S&P Global, is CARE's largest rival, with a market cap of roughly ₹29,000 to 30,800 crore versus CARE's ~₹5,000 to 5,100 crore as of mid-2026, and an estimated 65% share of India's rating market.
Who owns CARE Ratings / CareEdge?
CARE Ratings is a publicly listed, widely-held Indian company on BSE (534804) and NSE (CARERATING) since 26 December 2012, with no single foreign controlling parent, unlike peers CRISIL (S&P Global) and ICRA (Moody's-linked).
Has CARE Ratings had regulatory trouble with SEBI?
Yes, historically. SEBI fined CARE ₹1 crore in 2020 over delayed Reliance Communications downgrades, fined it ₹25 lakh in 2020 over IL&FS, and in 2023 banned former MD Rajesh Mokashi for two years over alleged DHFL rating interference.
How fast is CARE Ratings growing internationally?
CareEdge Global expanded to rate 45 countries within 18 months of its launch, positioning itself as the world's fourth-largest sovereign rating provider by coverage as of 29 May 2026, per an ORF analysis.
Timeline
  • 2026-05-29CareEdge Global reported rating 45 countries within 18 months of launch
  • 2026-03-31FY26 ends: consolidated revenue ₹473.07 crore (+18% YoY), profit ₹173.69 crore (+24% YoY)
  • 2025Launched Gen-AI tool EdgeAvira.ai via CareEdge Analytics
  • 2024-04CareEdge Global IFSC Ltd established in GIFT City
  • 2024CARE ESG Ratings Ltd received SEBI Category I ESG Rating Provider license
  • 2023SEBI banned former MD Rajesh Mokashi for two years over DHFL rating interference
  • 2020SEBI fined CARE ₹1 crore over delayed Reliance Communications downgrade
  • 2020SEBI fined CARE ₹25 lakh in IL&FS-related enforcement action
  • 2017-02Renamed from Credit Analysis & Research Limited to CARE Ratings Limited
  • 2012-12-26Listed on BSE and NSE
Revision history
21 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
S&P GlobalMoody'sIQVIA Holdings
More in Financial data and information services →
Sources